NLS Bavarian Nordic

Bavarian Nordic has announced the dosing of the first subject in the Phase 3 VANIR clinical trial of its investigational respiratory syncytial virus (RSV) vaccine candidate, MVA-BN RSV in older adults. The VANIR trial is a global, randomized, double-blind Phase 3 trial of the recombinant MVA-BN RSV vaccine in 20,000 adults aged 60 years and […]

Bavarian Nordic has entered into an exclusive license and supply agreement with Nuance Pharma, a Shanghai-based specialty pharmaceutical company. The agreement concerns the development and commercialization of MVA-BN RSV against respiratory syncytial virus (RSV) in adults in Chinese Mainland, Hong Kong, Macau, Taiwan, South Korea and certain Southeast Asian countries. The agreement entails clinical development, […]

The U.S. Food and Drug Administration has granted the designation for the company’s vaccine candidate for active immunization for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 60 years or older. The designation has been granted upon the assessment of preliminary clinical evidence for the vaccine candidate, MVA-BN […]

The company has initiated the first-in-human trial of MVA-BN WEV, a prophylactic vaccine candidate against the equine encephalitis virus – a rare, but potentially deadly illness. The program, which is funded by the United States Department of Defense (DOD) Joint Project Manager for Chemical, Biological, Radiation, and Nuclear Medical (JPM CBRN Medical) is a multi-year […]

Bavarian Nordic announces positive results from a Phase 3 pivotal study of its investigational, non-replicating smallpox vaccine, IMVAMUNE. The study achieved both of its primary endpoints, demonstrating IMVAMUNE’s efficacy in comparison to ACAM2000, the current US licensed replicating smallpox vaccine. Study details In this randomized, open-label study of 440 volunteers, the peak neutralizing antibodies induced by […]

Bavarian Nordic has entered into a joint collaboration with Evaxion Biotech, a Danish biotechnology company, and Technical University of Denmark (DTU), for the development of an MVA-BN-based vaccine against MRSA (Methicillin-resistant Staphylococcus aureus) using Evaxion’s computer-based technology to discover novel antigens. The same approach could potentially be used to target any other bacteria that have […]